JAK2V617F: more than a clonal marker?

被引：0

作者：

Tefferi, Ayalew ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA

来源：

LEUKEMIA & LYMPHOMA | 2009年 / 50卷 / 02期

关键词：

POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; ALLELE BURDEN; MUTATIONS; THERAPY;

D O I：

10.1080/10428190902717059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：154 / 155

页数：2

共 50 条

[41] Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms
Ueda, Koki
Ikeda, Kazuhiko
Ikezoe, Takayuki
Harada-Shirado, Kayo
Ogawa, Kazuei
Hashimoto, Yuko
Sano, Takahiro
Ohkawara, Hiroshi
Kimura, Satoshi
Shichishima-Nakamura, Akiko
Nakamura, Yuichi
Shikama, Yayoi
Mori, Tsutomu
Mason, Philip J.
Bessler, Monica
Morishita, Soji
Komatsu, Norio
Shide, Kotaro
Shimoda, Kazuya
Koide, Shuhei
Aoyama, Kazumasa
Oshima, Motohiko
Iwama, Atsushi
Takeishi, Yasuchika
BLOOD ADVANCES, 2017, 1 (15) : 1001 - 1015
[42] Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment
Hasan, S.
Cassinat, B.
Droin, N.
Le Couedic, J. P.
Favale, F.
Monte-Mor, B.
Lacout, C.
Fontenay, M.
Dosquet, C.
Chomienne, C.
Solary, E.
Villeval, J. L.
Casadevall, N.
Kiladjian, J. J.
Vainchenker, W.
Plo, I.
LEUKEMIA, 2014, 28 (02) : 460 - 463
[43] JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Santos, Fabio P. S.
Verstovsek, Srdan
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1098 - 1109
[44] JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan
Edahiro, Yoko
Morishita, Soji
Takahashi, Kochi
Hironaka, Yumi
Yahata, Yuriko
Sunami, Yoshitaka
Shirane, Shuichi
Tsutsui, Miyuki
Noguchi, Masaaki
Koike, Michiaki
Imai, Kiyotoshi
Kirito, Keita
Noda, Naohiro
Sekiguchi, Yuji
Tsuneda, Satoshi
Ohsaka, Akimichi
Araki, Marito
Komatsu, Norio
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (05) : 625 - 634
[45] Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
Yoenal-Hindilerden, Ipek
Sahin, Ezgi
Hindilerden, Fehmi
Daglar-Aday, Aynur
Nalcaci, Meliha
TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (03) : 174 - 182
[46] QUANTITATIVE EVALUATION OF JAK2V617F MUTATION AND BCR-ABL P210 TRANSLOCATION IN PATIENTS WITH SIMULTANEOUS JAK2V617F MUTATION AND BCR-ABL TRANSLOCATION
Abdullaev, A. O.
Treglazova, S. A.
Skorobogatova, A., V
Makarik, T., V
Stepanova, E. A.
Shukhov, O. A.
Turkina, A. G.
Melikyan, A. L.
Kovrigina, A. M.
Sudarikov, A. B.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2015, 60 (01): : 29 - 32
[47] JAK2V617F Mutation Is Not Associated with Thrombosis in Behcet Syndrome
Ar, M. Cem
Hatemi, Gulen
Ekizoglu, Seda
Bilgen, Hulya
Sacli, Sevgi
Buyru, A. Nur
Soysal, Teoman
Ulku, Birsen
Yazici, Hasan
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2012, 18 (04) : 421 - 426
[48] JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis
Sandra Guerra Xavier
Telma Gadelha
Glicínia Pimenta
Angela Maria Eugenio
Daniel Dias Ribeiro
Fernanda Mendes Gomes
Martin Bonamino
Ilana Renault Zalcberg
Nelson Spector
Digestive Diseases and Sciences, 2010, 55 : 1770 - 1777
[49] Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm
Poisson, Johanne
Tanguy, Marion
Davy, Hortense
Camara, Fatoumata
El Mdawar, Marie-Belle
Kheloufi, Marouane
Dagher, Tracy
Devue, Cecile
Lasselin, Juliette
Plessier, Aurelie
Merchant, Salma
Blanc-Brude, Olivier
Souyri, Michele
Mougenot, Nathalie
Dingli, Florent
Loew, Damarys
Hatem, Stephane N.
James, Chloe
Villeval, Jean-Luc
Boulanger, Chantal M.
Rautou, Pierre-Emmanuel
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05) : 2630 - 2643
[50] JAK2V617F allele burden is associated with transformation to myelofibrosis
Koren-Michowitz, Maya
Landman, Joseph
Cohen, Yoram
Rahimi-Levene, Naomi
Salomon, Ophira
Michael, Maria
Amariglio, Ninette
Nagler, Arnon
LEUKEMIA & LYMPHOMA, 2012, 53 (11) : 2210 - 2213

← 1 2 3 4 5 →